CytomX Q2 2026: Cash Runway to H2 2028, Regeneron Deal Expanded, Varseta-M Dose Optimization Complete
CTMX sits 90% above its 52-week low of $1.72.
Summary
CytomX's Q2 2026 filing shows a fortified cash position extending runway to H2 2028, an expanded Regeneron partnership, and key clinical progress for Varseta-M and CX-801.
Key Events · Earnings and Guidance · CTMX
-
Cash Runway Extended to H2 2028
Cash, equivalents, and short-term investments totaled $330.3M as of June 30, 2026, up from $137.1M at year-end 2025, driven by a $234.2M public offering in March 2026. Management expects this to fund operations into at least the second half of 2028.
-
Regeneron Collaboration Expanded
The amended Regeneron deal added up to eight new targets, with two selected in June 2026 for a $37M upfront fee (received in July). Total potential milestones now reach approximately $4B, plus royalties.
-
Varseta-M Dose Optimization Complete
Enrollment in the Varseta-M dose optimization cohorts (8.6 mg/kg and 10 mg/kg) is complete. Additional Phase 1 data expected by end of 2026 to support monotherapy dose selection and a potential registrational trial in late-line CRC starting in H1 2027.
-
CX-801 Combination Trial Advancing
The Phase 1 dose escalation of CX-801 in combination with KEYTRUDA has cleared the third dose level. Initial clinical data from the combination portion is expected in the first half of 2027.
Analysis · CTMX · Life Sciences
CytomX reported a $20.7M net loss on $1.4M in revenue, but the real story is the balance sheet. With $330.3M in cash and investments, the company has extended its runway into at least the second half of 2028 — a critical survival metric for a clinical-stage biotech. The Regeneron collaboration expansion, which brought in a $37M upfront payment in July, adds up to $4B in potential milestones and validates the PROBODY platform. On the clinical front, Varseta-M dose optimization is complete, setting the stage for a registrational trial design by year-end, while CX-801 combination data is expected in the first half of 2027. These milestones keep the pipeline on track, but the company remains deeply unprofitable and will need to execute on clinical catalysts to justify its valuation.
At the time of this filing, CTMX was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $733.7M. The 52-week trading range was $1.72 to $8.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.